Kelly Baker, Director of Clinical and Regulatory Affair, adds: The completion of enrollment in our first IDE is set in motion a further confirmation of our unique product development and regulatory approval process and the stage for our extensive conservation efforts. We are very grateful to our dedicated researchers and employees as their contributions were critical to the successful completion of enrollment. We look forward to the further analysis of patients and PMA submission for ultimate market entry within the next two years order here . .

Globus plans two more U.S. IDE to initiate clinical trials this year on motion preservation devices. Three of the Company posterior motion preservation technologies : the TRIUMPH Posterolateral disc that TRANSITION Posterior Dynamic Stabilization, and Flexus Inspinous process spacer system are under the numerous research papers and presentations about the company’s products at this week’s Spine Arthroplasty Society meeting in Miami, Florida.

Health Behaviour News Service Center for the Development of on Health 2000 Florida Ave.